Open AccessPlasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia
Author(s) -
Wanlong Ma,
Richard Tseng,
M. Gorre,
Iman Jilani,
Michael J. Keating,
Hagop M. Kantarjian,
Jorge Cortes,
Susan O’Brien,
Francis J. Giles,
Mäher Albitar
Publication year - 2007
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.10360
Subject(s) - myeloid leukemia , imatinib , messenger rna , reverse transcriptase , imatinib mesylate , real time polymerase chain reaction , medicine , leukemia , cancer research , bone marrow , philadelphia chromosome , immunology , polymerase chain reaction , biology , oncology , gene , genetics , chromosomal translocation
Quantitation of BCR-ABL mRNA is emerging as the standard of care to monitor the status of chronic myeloid leukemia (CML). Peripheral blood plasma was analyzed in this study because of previous detection of nucleic acids and proteins from tumor cells in plasma samples.